Show simple item record

dc.contributor.authorJones, RLen_US
dc.contributor.authorThway, Ken_US
dc.date.accessioned2018-02-16T11:40:26Z
dc.date.issued2017-10en_US
dc.identifier.citationNature reviews. Clinical oncology, 2017, 14 (10), pp. 589 - 590en_US
dc.identifier.issn1759-4774en_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/1197
dc.identifier.eissn1759-4782en_US
dc.identifier.doi10.1038/nrclinonc.2017.118en_US
dc.formatPrint-Electronicen_US
dc.format.extent589 - 590en_US
dc.languageengen_US
dc.language.isoengen_US
dc.subjectHumansen_US
dc.subjectSarcomaen_US
dc.subjectChemotherapy, Adjuvanten_US
dc.subjectNeoadjuvant Therapyen_US
dc.titleSarcoma: Does histotype-tailored neoadjuvant therapy improve outcomes?en_US
dc.typeJournal Article
rioxxterms.versionofrecord10.1038/nrclinonc.2017.118en_US
rioxxterms.licenseref.startdate2017-10en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfNature reviews. Clinical oncologyen_US
pubs.issue10en_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Sarcoma Clinical Trials (R Jones)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Sarcoma Clinical Trials (R Jones)/Sarcoma Clinical Trials (R Jones) (hon.)
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublisheden_US
pubs.volume14en_US
pubs.embargo.termsNot knownen_US
icr.researchteamSarcoma Clinical Trials (R Jones)en_US
dc.contributor.icrauthorJones, Robinen_US
dc.contributor.icrauthorThway, Khinen_US
dc.contributor.icrauthorMarsden,en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record